Home / Advocacy



The AMP advocacy program endeavors to inform and influence public policy affecting molecular pathology.  AMP represents its membership to the federal agencies and members of Congress regarding professional and reimbursement issues - reaching out to fellow professional associations, industry and other association partners to accomplish common goals. 

In 2015, AMP plans to continue addressing many regulatory and reimbursement forces adversely affecting molecular diagnostic testing.In January, AMP released a white paper titled A Molecular Diagnostic Perfect Storm: The Convergence of Regulatory & Reimbursement Forces that Threaten Patient Access to Innovations in Genomic Medicine detailing these challenges and utilizes it to support advocacy initiatives.

Position statements, comments, and letters are usually generated by our Professional Relations and Economic Affairs Committees, though our Clinical Practice and Training & Education Committees do advocate in their areas. We invite you to explore AMP's Position Statements and Letters. For more information, please contact

View all AMP Position Statements and Letters

Just released:

CLIA Modernization Proposal

Learn More


Genomic Sequencing Procedure Cost and Value Models-Free Download Available!


Updates on Laboratory Developed Procedures (LDPs)


Learn more about AMP's CLIA Modernization Proposal


AMP's Principles for Oversight of LDPs


AMPs Comments to House E&C Committee on Regulation of In Vitro Clinical Tests Draft Legislation


AMP's written comments to FDA on LDPs


Signs from the 2014 Annual Meeting:  Are you ready to be a "manufacturer"?


AMP Position Statement: Revisiting Oversight and Regulation of Molecular-Based Laboratory-Developed Tests


FDA's website devoted to all information relevant to the draft framework: